predict and optimize stem cell differentiation, enabling us to manufacture any cell and tissue in the human body at scale with unparalleled precision.

Rooted in the groundbreaking research from the Carazo Salas lab at the University of Bristol, our technology represents the intersection of cell biology, computer vision, engineering, and machine learning. We are committed to translating next-generation science from research into real-world applications, addressing some of the most pressing challenges in healthcare.

Our dedicated team, led by Founder & CEO Rafael Carazo, is supported by a network of visionary investors who were early backers of AI pioneers such as DeepMind, Exscientia, Recursion, and Wayve. Additionally, we benefit from the support of the founder/CEO of Abcam, a leader in the antibody business. With $2.5M in annual revenue and a seed funding round, CellVoyant is well-positioned to make a significant impact on the biotechnology landscape.

Join us on our journey as we strive to make transformative therapies a reality. At CellVoyant, we are not just advancing science—we are shaping the future of medicine. Explore opportunities to collaborate, invest, or learn more about our innovative solutions by visiting our website at https://cellvoyant.tech or contacting us at admin@cellvoyant.tech.